Sidra Medicine

sidra.org

Sidra Medicine provides specialized healthcare to women, children, and young people from Qatar and around the world. Established by Qatar Foundation for Education, Science and Community Development, Sidra Medicine embraces best practice medical education, innovative biomedical and clinical research and discovery, and exceptional patient and family focused care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

news image

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

news image

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More

Pharmacy Market

ELIXIR ANNOUNCES THE NEXT WAVE OF INNOVATION FOR PHARMACY BENEFITS TECHNOLOGY PLATFORM

Businesswire | May 29, 2023

news image

Elixir, a pharmacy benefit management company owned by Rite Aid has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface. "Already a leader in the industry, Laker Software is going from good to great,” said Jeff Mallad, VP, PBM Technology Sales for Elixir. "Elixir’s technology platform is one of the fastest a...

Read More

Business Insights

ABLEXIS AND ALIVAMAB DISCOVERY SERVICES ANNOUNCE AGREEMENTS WITH ALMIRALL TO ACCELERATE ANTIBODY DRUG DISCOVERY AND DEVELOPMENT

Ablexis, LLC, | January 31, 2022

news image

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (“ADS”), a leader in the discovery of superior antibody-based therapeutics, today announced a multi-target licensing agreement between Ablexis and Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall. Under the terms of the license wi...

Read More
news image

Pharmacy Market

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More
news image

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More
news image

Pharmacy Market

ELIXIR ANNOUNCES THE NEXT WAVE OF INNOVATION FOR PHARMACY BENEFITS TECHNOLOGY PLATFORM

Businesswire | May 29, 2023

Elixir, a pharmacy benefit management company owned by Rite Aid has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface. "Already a leader in the industry, Laker Software is going from good to great,” said Jeff Mallad, VP, PBM Technology Sales for Elixir. "Elixir’s technology platform is one of the fastest a...

Read More
news image

Business Insights

ABLEXIS AND ALIVAMAB DISCOVERY SERVICES ANNOUNCE AGREEMENTS WITH ALMIRALL TO ACCELERATE ANTIBODY DRUG DISCOVERY AND DEVELOPMENT

Ablexis, LLC, | January 31, 2022

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (“ADS”), a leader in the discovery of superior antibody-based therapeutics, today announced a multi-target licensing agreement between Ablexis and Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall. Under the terms of the license wi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us